Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2

被引:241
作者
Patel, Zarana S. [1 ]
Yamamoto, Masaya [2 ]
Ueda, Hiroki [2 ]
Tabata, Yasuhiko [2 ]
Mikos, Antonios G. [1 ]
机构
[1] Rice Univ, Dept Bioengn, Houston, TX 77251 USA
[2] Kyoto Univ, Inst Frontier Med Sci, Dept Biomat, Field Tissue Engn,Sakyo Ku, Kyoto 6068507, Japan
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
controlled release; growth factor delivery; bone morphogenetic protein; gelatin microparticles; bone tissue engineering;
D O I
10.1016/j.actbio.2008.04.002
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
This work evaluated gelatin microparticles and biodegradable composite scaffolds for the controlled release of bone morphogenetic protein-2 (BMP-2) in vitro and in vivo. Gelatin crosslinking (10 and 40 mM glutaraldehyde), BMP-2 dose (6 and 60 ng BMP-2 per mg dry microparticles), buffer type (phosphate buffered saline (PBS) and collagenase-containing PBS), and gelatin type (acidic and basic) were investigated for their effects on BMP-2 release. Release profiles were also observed using poly(lactic-co-glycolic acid) (PLGA) microparticles with varying molecular weights (8300 and 57,500). In vitro and in vivo studies were conducted using radiolabeled BMP-2; the chloramine-T method was preferred over Bolton-Hunter reagent for radioiodination with this system. BMP-2 release from PLGA microparticles resulted in a moderate burst release followed by minimal cumulative release, while BMP-2 release from gelatin microparticles exhibited minimal burst release followed by linear release kinetics in vitro. Growth factor dose had a small effect on its normalized release kinetics probably because of an equilibrium between gelatin-bound and unbound BMP-2. Differences in release from acidic and basic gelatin microparticles may result from the different pretreatment conditions used for gelatin synthesis. The in vitro release kinetics for both gelatin microparticles alone and within composite scaffolds were dependent largely on the extent of gelatin crosslinking; varying buffer type served to confirm that controlled release relies on enzymatic degradation of the gelatin for controlled release. Finally, in vivo studies with composite scaffolds exhibited minimal burst and linear release up to 28 days. In summary, dose effects on BMP-2 release were found to be minimal while varying gelatin type and release medium can alter release kinetics. These results demonstrate that it systematic control of BMP-2 delivery from gelatin microparticles can be achieved by altering the extent of basic gelatin crosslinking. (C) 2008 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1126 / 1138
页数:13
相关论文
共 47 条
[1]  
BOLTON AE, 1973, BIOCHEM J, V133, P29
[2]   Expression of bone morphogenetic proteins in fracture healing [J].
Bostrom, MPG .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1998, (355) :S116-S123
[3]  
BURCHARDT H, 1983, CLIN ORTHOP RELAT R, P28
[4]  
Cornell CN, 1998, CLIN ORTHOP RELAT R, pS267
[5]  
Duggirala S S, 1996, Pharm Dev Technol, V1, P11, DOI 10.3109/10837459609031413
[6]   Soft and hard tissue response to photocrosslinked poly(propylene fumarate) scaffolds in a rabbit model [J].
Fisher, JP ;
Vehof, JWM ;
Dean, D ;
van der Waerden, JPCM ;
Holland, TA ;
Mikos, AG ;
Jansen, JA .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 2002, 59 (03) :547-556
[7]   Collagen sponges for bone regeneration with rhBMP-2 [J].
Geiger, M ;
Li, RH ;
Friess, W .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (12) :1613-1629
[8]   Fracture healing as a post-natal developmental process: Molecular, spatial, and temporal aspects of its regulation [J].
Gerstenfeld, LC ;
Cullinane, DM ;
Barnes, GL ;
Graves, DT ;
Einhorn, TA .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (05) :873-884
[9]   PREPARATION OF 131I-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY [J].
GREENWOOD, FC ;
HUNTER, WM .
BIOCHEMICAL JOURNAL, 1963, 89 (01) :114-&
[10]  
Haralson M. A., 1995, EXTRACELLULAR MATRIX